Journal of Clinical Cardiology

While the global COVID-19 pandemic has challenged the entire humanity and health systems, it also triggered researchers to urgently perform clinical trials to assess the safety and efficacy of many agents and modalities to combat COVID-19. As of April 22, over 650 clinical studies have been registered both in USA and internationally. Results from these studies are also coming at a brisk pace in this unprecedented emergency.

Ketamine has long been used in the field of anesthesia [1]. Its rapid and long-acting analgesic effects associated with its dissociative properties have also established its use in prehospital and emergency department patients.

The currently ongoing coronavirus pandemic, the SARSCOV- 2, interchangeably referred to as the COVID-19 infection, has in a short span of time altered the ways and means of almost all of mankind. So strong has been its effect that all human activity ceased in one way or another for a considerable time, led to significant loss of life and economic drain of.

In a recent paper, we introduced a variant of the classical Simeoni tumor growth model, and illustrated its value in assessing tumor growth in a reproducible mouse model for mammary tumors. Our modification consisted of incorporating delay differential equations in the mathematical formulation of the Simeoni model, to represent the delay in drug action often observed under chemotherapeutic or immunotherapeutic regimens.

Five months into the COVID-19 pandemic, the U.S. death toll from the virus has now surpassed 100,000 people. Many more cases remain nationwide, while an unknown number of patients currently harbor the virus asymptomatically. While health officials are now optimistic regarding the decline in prevalence and number of deaths due to COVID-19 and the possibility of a vaccine by the fall, we cannot lose sight of the bigger picture: the next pandemic.

Rituximab is a chimeric (20% rodent and 80% human) monoclonal antibody that binds to the CD20 antigen present on the cell surface and leads to depletion of mature B-cells [1,2]. It is the first approved monoclonal antibody to be used in the therapy of indolent B-cell non- Hodgkin’s lymphoma and chronic lymphocytic leukemia

In the article, “Mental Health Framework: Coronavirus pandemic in post-Katrina New Orleans” [1], Shervington and Richardson offer recommendations about how to anticipate and address disaster-related, trauma exposures associated with the coronavirus pandemic

In January 2020, the World Health Organization (WHO) classified COVID-19 to be a Public Health Emergency of International Concern and declared it a pandemic on March 11, 2020 [1]. Over one hundred and eighty-five million people have been infected by SARS-CoV-2 and roughly four million have died worldwide so far

Breast cancer is the second most common cancer worldwide, affecting nearly one in eight women. Accurate cancer staging is essential for determining the patient’s prognosis and for choosing the appropriate treatment.

The COVID-19 pandemic has provoked a global, rapid increase of cases due to the high infectivity of the etiological agent, COVID-19 virus. In February 2021, over 110 million confirmed COVID-19 cases with 1 million deaths were reported worldwide (www.who.int).

The precise role of corticosteroids for treatment of coronavirus disease 2019 (COVID-19) is unclear due to lack of randomized trials.

Since December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused by 2019 Novel Coronavirus (2019-nCoV) has resulted in 89,000 cases of Corona Virus Disease 2019 (COVID-19), formerly known as Novel Coronavirus Pneumonia (NCP) in China, including 2,450 deaths.

In 2020 we published a series of 18 patients who underwent neoadjuvant chemotherapy (NACT) and vaginal radical trachelectomy (VRT) as a fertility sparing alternative in stage 1B2 cervical cancer.

COVID-19 is the new emerging viral infection that already cause global public health problem [1-3]. More than 220 countries/territories are already attacked and there are more than 17 million patients around the world

After one year in a pandemic, we mourn the loss of over half a million lives in the United States, and over four million worldwide, and remain concerned over the challenges facing the families of 35 million people in the United States, and 200 million worldwide, who have suffered from cases of COVID-19.

In light of the current pandemic from rapid transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) and significant morbidity, there has been inconsistent medical guidance given to the public regarding the wearing of non-medical improvised fabric masks or face coverings to reduce the transmission of COVID-19.

At the beginning of Covid-19 pandemic, we proposed to use hydroxychloroquine (HCQ) and intranasal interferon (IFN) a-2b spray to prevent SARS-CoV-2.

Telehealth has been around since the 1960s as a healthcare delivery modality, though it did not gain widespread acceptance as a viable and reliable clinical tool until the late 1990s, when digital imaging and high speed, high bandwidth telecommunications technology became widely available [1]. Historical boundaries to its acceptance and

Since the declaration of COVID-19 as a pandemic in March 2020 [1], there have been more than 100 million reported cases of COVID-19 worldwide and more than 2.1 million deaths [2].

The manufacture of scaffolds for wound healing has become important, especially the formation of tissuespecific scaffolding. In order to create scaffolds, it is essential to mimic the chemical composition, physical morphology and biological functions of the human body. Scaffolds can be created by using synthetic polymers (e.g. polycaprolactone) or natural polymers (e.g. chitosan) or a combination of both. The addition of natural polymers can be very advantageous as they can avoid